Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

INVO

INVO BioScience (INVO)

INVO BioScience Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:INVO
일자시간출처헤드라인심볼기업
2024/05/2205:39Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:INVOINVO BioScience Inc
2024/05/1605:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2024/05/1605:15GlobeNewswire Inc.INVO Reports Record First Quarter 2024 Financial ResultsNASDAQ:INVOINVO BioScience Inc
2024/05/0706:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2024/04/1723:25AllPennyStocks.comMicro Cap Massively Bid Up Before Opening BellNASDAQ:INVOINVO BioScience Inc
2024/04/1705:59GlobeNewswire Inc.INVO Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:INVOINVO BioScience Inc
2024/02/0700:24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:INVOINVO BioScience Inc
2024/02/0123:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2024/01/2322:00GlobeNewswire Inc.NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)NASDAQ:INVOINVO BioScience Inc
2024/01/1722:00GlobeNewswire Inc.INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board DirectorsNASDAQ:INVOINVO BioScience Inc
2024/01/1707:29Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:INVOINVO BioScience Inc
2024/01/1106:46Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:INVOINVO BioScience Inc
2024/01/1106:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2024/01/0407:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2023/12/2907:04Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:INVOINVO BioScience Inc
2023/12/2907:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2023/12/1407:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:INVOINVO BioScience Inc
2023/12/1406:53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2023/12/1122:00PR Newswire (US)NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood JournalNASDAQ:INVOINVO BioScience Inc
2023/11/2907:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2023/11/2823:00PR Newswire (US)INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNASDAQ:INVOINVO BioScience Inc
2023/11/2503:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:INVOINVO BioScience Inc
2023/11/2106:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2023/11/1406:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2023/11/1406:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INVOINVO BioScience Inc
2023/11/1406:01PR Newswire (US)INVO Reports Record Third Quarter 2023 Financial ResultsNASDAQ:INVOINVO BioScience Inc
2023/11/1323:23Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:INVOINVO BioScience Inc
2023/11/1323:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INVOINVO BioScience Inc
2023/11/1323:12Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:INVOINVO BioScience Inc
2023/11/1023:00PR Newswire (US)NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending MergerNASDAQ:INVOINVO BioScience Inc
 검색 관련기사 보기:NASDAQ:INVO